Sustained pricing pressure in agrochemicals and pharma
Pricing remains subdued due to persistent dumping from China; recovery depends on China's anti-involution actions.
medium · management_commentaryAarti Drugs Limited — Q3 FY26
Aarti Industries reported Q3 FY26 revenue of ₹2,492 crore (up 11% QoQ) and EBITDA of ₹323 crore (up 11% QoQ), driven by volume growth in MMA and other products.
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Zone 4 ramp-up delays
Specialty products require customer qualification cycles; meaningful utilization may take up to 2 years.
medium · management_commentaryUS tariff impact on PDA chain
PDA product chain faced volume and pricing pressure due to large US dependency; recovery hinges on trade deal details.
medium · analyst_questionPotential negative impact from EU imports into India
Analyst raised risk of European competitors importing into India under FTA; management downplayed but acknowledged possibility.
low · analyst_question